Introduction {#sec1}
============

Dynamic biomolecules often undergo large-scale structural changes and visit distinct conformational states during their biological function.^[@ref1]^ It is of great biological and pharmaceutical interest to characterize their structures and conformational transition pathways. Ideally, detailed free energy landscapes are sought to understand the functional mechanisms of biomolecules in a quantitative manner. However, due to large energy barriers, conformational transitions of biomolecules usually take place on time scales of milliseconds or even longer.^[@cit1a],[@ref2]^ This has presented a grand challenge for computational molecular dynamics (MD) simulations that are limited to typically hundreds-of-nanoseconds to tens-of-microseconds.^[@ref3]^

To address this challenge, biasing simulation methods have been found useful in enhanced sampling and free energy calculation of the biomolecules. These methods include umbrella sampling,^[@ref4]^ conformational flooding,^[@ref5]^ metadynamics,^[@ref6]^ adaptive biasing force (ABF) calculations,^[@ref7]^ and orthogonal space sampling,^[@ref8]^ etc. During the simulations, a potential or force bias is applied along certain reaction coordinates (or collective variables) to facilitate the biomolecular conformational transitions across high-energy barriers. Typical reaction coordinates include atom distances, torsional dihedrals, root-mean-square deviation (RMSD) relative to a reference configuration, eigenvectors generated from the principal component analysis,^[@cit5b]^ and so on. The definition of the reaction coordinates, however, often requires expert knowledge of the studied systems. Furthermore, the predefined reaction coordinates largely place constraints on the pathway and conformational space to be sampled during the biasing simulations. It often leads to slow convergence of the simulations when important reaction coordinates are missed during the simulation setup.^[@cit6b]^

Accelerated molecular dynamics (aMD) is an enhanced sampling technique that works often by adding a non-negative boost potential to smoothen the biomolecular potential energy surface. The boost potential, Δ*V*, decreases the energy barriers and thus accelerates transitions between the different low-energy states.^[@ref9]^ With this, aMD is able to sample distinct biomolecular conformations and rare barrier-crossing events that are not accessible to conventional MD (cMD) simulations. Unlike the previously mentioned biasing simulation methods, aMD does not require predefined reaction coordinate(s), which can be advantageous for exploring the biomolecular conformational space without a priori knowledge or restraints. aMD has been successfully applied to a number of biological systems, ([@ref10]) and hundreds-of-nanosecond aMD simulations have been shown to capture millisecond-time-scale events in both globular and membrane proteins.^[@ref11]^

While aMD has been demonstrated to greatly enhance conformational sampling of biomolecules, it suffers from large energetic noise during reweighting.^[@ref12]^ The boost potential applied in aMD simulations is typically on the order of tens-to-hundreds of kilocalories per mole, which is much greater in magnitude and wider in distribution than that of other biasing simulation methods that make use of predefined reaction coordinates (e.g., several kilocalories per mole). It has been a long-standing problem to accurately reweight aMD simulations and recover the original free energy landscapes, especially for large proteins.^[@ref13]^ Our recent studies showed that when the boost potential follows near-Gaussian distribution, cumulant expansion to the second order provides improved reweighting of aMD simulations compared with the previously used exponential average and Maclaurin series expansion reweighting methods.^[@ref14]^ The reweighted free energy profiles are in good agreement with the long-time-scale cMD simulations as demonstrated on alanine dipeptide and fast-folding proteins.^[@ref15]^ However, such improvement is limited to rather small systems (e.g., proteins with less than ∼35 amino acid residues).^[@ref15]^ In simulations of larger systems, the boost potential exhibits significantly wider distribution and does not allow for accurate reweighting.

Here, a Gaussian accelerated molecular dynamics (GaMD) approach is presented to reduce the energetic noise for simultaneous unstrained enhanced sampling and free energy calculation of biomolecules, even for large proteins. GaMD makes use of harmonic functions to construct the boost potential that is adaptively added to the biomolecular potential energy surface. A minimal set of simulation parameters is dynamically adjusted to control the magnitude and distribution width of the boost potential. As such, the resulting boost potential follows Gaussian distribution and allows for accurate reweighting of the simulations using cumulant expansion to the second order. In this study, GaMD is demonstrated on unconstrained simulations of the alanine dipeptide, chignolin folding, and ligand binding to the T4-lysozyme.

Methods {#sec2}
=======

Gaussian Accelerated Molecular Dynamics {#sec2.1}
---------------------------------------

Gaussian accelerated molecular dynamics enhances the conformational sampling of biomolecules by adding a harmonic boost potential to smoothen the system potential energy surface ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). Consider a system with *N* atoms at positions = {~1~,\...,~*N*~} . When the system potential *V*() is lower than a threshold energy, *E*, a boost potential is added aswhere *k* is the harmonic force constant. The modified system potential, *V*\*() = *V*() + Δ*V*(), is given byOtherwise, when the system potential is above the threshold energy, i.e., *V*() ≥ *E*, the boost potential is set to zero and *V*\*() = *V*().

![Scheme illustration of Gaussian accelerated molecular dynamics (GaMD). When the threshold energy is set to the maximum potential (*E* = *V*~max~), the system potential energy surface is smoothened by adding a harmonic boost potential that follows Gaussian distribution. The coefficient *k*~0~ in the range of 0--1 determines the magnitude of the applied boost potential. With greater *k*~0~, higher boost potential is added to the original energy surface in conventional molecular dynamics (cMD), which provides enhanced sampling of biomolecules across decreased energy barriers.](ct-2015-00436c_0002){#fig1}

In order to smoothen the potential energy surface for enhanced sampling, the boost potential needs to satisfy the following criteria. First, for any two arbitrary potential values *V*~1~() and *V*~2~() found on the original energy surface, if *V*~1~() \< *V*~2~(), Δ*V* should be a monotonic function that does not change the relative order of the biased potential values; i.e., *V*~1~^\*^() \< *V*~2~^\*^(). By replacing *V*\*() with [eq [2](#eq2){ref-type="disp-formula"}](#eq2){ref-type="disp-formula"} and isolating *E*, we then obtainSecond, if *V*~1~() \< *V*~2~(), the potential difference observed on the smoothened energy surface should be smaller than that of the original; i.e., *V*~2~^\*^() -- *V*~1~^\*^() \< *V*~2~() -- *V*~1~(). Similarly, by replacing *V*\*() with [eq [2](#eq2){ref-type="disp-formula"}](#eq2){ref-type="disp-formula"}, we can deriveWith *V*~min~ ≤ *V*~1~() \< *V*~2~() ≤ *V*~max~, we need to set the threshold energy *E* in the following range by combining [eqs [3](#eq3){ref-type="disp-formula"}](#eq3){ref-type="disp-formula"} and [4](#eq4){ref-type="disp-formula"}:where *V*~min~ and *V*~max~ are the system minimum and maximum potential energies. To ensure that [eq [5](#eq5){ref-type="disp-formula"}](#eq5){ref-type="disp-formula"} is valid, *V*~max~ ≤ *V*~min~ + (1/*k*) and *k* has to satisfy the following:We define *k* ≡ *k*~0~(1/(*V*~max~ -- *V*~min~)); then 0 \< *k*~0~ ≤ 1. As illustrated in [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}, *k*~0~ determines the magnitude of the applied boost potential. With greater *k*~0~, higher boost potential is added to the potential energy surface, which provides enhanced sampling of biomolecules across decreased energy barriers.

Third, the standard deviation of Δ*V* needs to be small enough (i.e., narrow distribution) to ensure accurate reweighting using cumulant expansion to the second order:^[@ref14]^where *V*~av~ and σ~*V*~ are the average and standard deviation of the system potential energies and σ~Δ*V*~ is the standard deviation of Δ*V* with σ~0~ as a user-specified upper limit (e.g., 10*k*~B~T) for accurate reweighting.

Provided [eq [5](#eq5){ref-type="disp-formula"}](#eq5){ref-type="disp-formula"} gives the range of threshold energy *E*, when *E* is set to the lower bound *E* = *V*~max~, we plug in *E* and *k* and obtainWe define the right-hand side in [eq [8](#eq8){ref-type="disp-formula"}](#eq8){ref-type="disp-formula"} as *k*~0~^′^ = (σ~0~/σ~*V*~)((*V*~max~ -- *V*~min~)/(*V*~max~ -- *V*~av~)). For efficient enhanced sampling with the highest possible acceleration, *k*~0~ can then be set to its upper bound asThe greater σ~Δ*V*~ that is obtained from the original potential energy surface (particularly for large biomolecules), the smaller *k*~0~ may be applicable to allow for accurate reweighting. Alternatively, when the threshold energy *E* is set to its upper bound *E* = *V*~min~ + (1/*k*) according to [eq [5](#eq5){ref-type="disp-formula"}](#eq5){ref-type="disp-formula"}, we plug in *E* and *k* in [eq [7](#eq7){ref-type="disp-formula"}](#eq7){ref-type="disp-formula"} and obtainWe define the right-hand side in [eq [10](#eq10){ref-type="disp-formula"}](#eq10){ref-type="disp-formula"} as *k*~0~^″^ ≡ (1 -- (σ~0~/σ~*V*~)) ((*V*~max~ -- *V*~min~)/(*V*~av~ -- *V*~min~)). When *k*~0~^″^ ≤ 0 with σ~*V*~ ≤ σ~0~, *k*~0~ can be theoretically set to any value between zero and 1, although *k*~0~ = 1 is applied in this case for the current implementation of GaMD (See [Appendix A](#app1){ref-type="other"}). Note that a smaller *k*~0~ will give higher threshold energy *E*, but smaller force constant *k*. When 0 \< *k*~0~^″^ ≤ 1, *k*~0~ can be set to either *k*~0~^″^ for the highest threshold energy *E* or its upper bound 1.0 for the greatest force constant *k*. In this case *k*~0~ = *k*~0~^″^ is applied in the current GaMD implementation. When *k*~0~^″^ \> 1, we have to lower the threshold energy *E* to ensure that 0 \< *k*~0~ ≤ 1; e.g., *E* = *V*~max~ for default *k*~0~ = 1.

Given *E* and *k*~0~, we can calculate the boost potential asSimilar to aMD, GaMD provides options to add only the total potential boost Δ*V*~P~, only dihedral potential boost Δ*V*~D~, or the dual potential boost (both Δ*V*~P~ and Δ*V*~D~). The dual-boost simulation generally provides higher acceleration than the other two types of simulations for enhanced sampling.^[@cit9b]^ The simulation parameters comprise of the threshold energy values and the effective harmonic force constants, *k*~0P~ and *k*~0D~ for the total and dihedral potential boost, respectively.

To characterize the extent to which Δ*V* follows Gaussian distribution, its distribution anharmonicity, γ, is calculated as was done previously:^[@ref14]^where Δ*V* is dimensionless as divided by *k*~B~*T* with *k*~B~ and *T* being the Boltzmann constant and system temperature, respectively, and *S*~max~ = (1/2) ln(2*πeσ*~Δ*V*~^2^) is the maximum entropy of Δ*V*.^[@ref16]^ When γ is zero, Δ*V* follows exact Gaussian distribution with sufficient sampling. Reweighting by approximating the exponential average term with cumulant expansion to the second order is able to accurately recover the original free energy landscape ([Appendix B](#app2){ref-type="other"}). As γ increases, the Δ*V* distribution becomes less harmonic and the reweighted free energy profile obtained from cumulant expansion to the second order deviates from the original. As demonstrated on the alanine dipeptide, chignolin, and T4-lysozyme in this study, a Gaussian distribution of the boost potential is normally achieved in the GaMD simulations. The anharmonicity of Δ*V* distribution serves as an indicator of the enhanced sampling convergence and accuracy of the reweighted free energy.

Simulation Protocols {#sec2.2}
--------------------

GaMD is currently implemented in the GPU version of AMBER 12^[@ref17]^ (see [Appendix A](#app1){ref-type="other"} for implementation details). Simulations of the alanine dipeptide, chignolin, and T4-lysozyme were performed using the AMBER ff99SB force field on GPUs.^[@ref18]^ The simulated systems were built using the Xleap module of the AMBER package. Alanine dipeptide and chignolin were constructed as described previously.^[@ref19]^ For T4-lysozyme, the ligand benzene was removed from the X-ray crystal structure of the Leu99Ala mutant (Protein Data Bank (PDB), 181L). Another four benzene molecules were placed in the bulk solvent at least 40 Å away from the ligand-binding site in the starting configuration. By solvating the structures in a TIP3P^[@ref20]^ water box that extends 8--10 Å from the solute surface, the alanine dipeptide system contained 630 water molecules, 2,211 waters for chignolin, and 9,011 waters for T4-lysozyme. The total number of atoms in the three systems are 1,912; 6,773; and 29,692 for alanine dipeptide, chignolin, and T4-lysozyme, respectively ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}).

###### Biomolecular Model Systems Simulated with GaMD in the Present Study (*N*~res~ and *N*~atoms~, Number of Residues and System Atoms, Respectively; Δ*V*~av~ and σ~Δ*V*~, Average, Standard Deviation of the Boost Potential, Δ*V*)

  system              *N*~res~   *N*~atoms~   GaMD         Δ*V*~av~ (kcal/mol)   σ~Δ*V*~ (kcal/mol)
  ------------------- ---------- ------------ ------------ --------------------- --------------------
  alanine dipeptide   2          1,912        30 ns × 3    10.9                  2.9
  chignolin           10         6,773        300 ns × 3   9.8                   2.4
  T4-lysozyme         162        29,692       800 ns × 4   36.3                  4.7
                                              1800 ns                             

Periodic boundary conditions were applied for all of the simulation systems. Bonds containing hydrogen atoms were restrained with the SHAKE algorithm,^[@ref21]^ and a 2 fs time step was used. Weak coupling to an external temperature and pressure bath was used to control both temperature and pressure.^[@ref22]^ The electrostatic interactions were calculated using the PME (particle mesh Ewald summation)^[@ref23]^ with a cutoff of 8.0 Å for long-range interactions.

The three systems were initially minimized for 2,000 steps using the conjugate gradient minimization algorithm, and then the solvent was equilibrated for 50 ps in an isothermal--isobaric (*NPT*) ensemble with the solute atoms fixed. Another minimization was performed with all atoms free, and the systems were slowly heated to 300 K over 500 ps. Final system equilibration was achieved by a 200 ps isothermal--isovolumetric (*NVT*) and 400 ps *NPT* run to ensure that the water box of the simulated systems had reached the appropriate density.

In the present study, the system threshold energy is set as *E* = *V*~max~ for all GaMD simulations. The maximum, minimum, average, and standard deviation values of the system potential (*V*~max~, *V*~min~, *V*~av~, and σ~*V*~) were obtained from an initial 2 ns *NVT* simulation with no boost potential. For optimal acceleration, the greatest σ~0~ and *k*~0~ were determined through short testing simulations (e.g., 2 ns): with increasing σ~0~, either *k*~0~ calculated using [eq [9](#eq9){ref-type="disp-formula"}](#eq9){ref-type="disp-formula"} reaches 1.0 (highest acceleration level) or σ~Δ*V*~ reaches 10*k*~B~*T* (the upper limit of the Δ*V* distribution width for accurate reweighting). Each GaMD simulation proceeds with a 2 ns equilibration run, followed by production simulations.

Testing simulations were performed with either the "total potential boost" or "dihedral potential boost" only to identify the optimal σ~0~ and *k*~0~ acceleration parameters ([Supporting Information](#notes-1){ref-type="notes"} Tables S1--S3). Long-time dual-boost GaMD simulations were then obtained for analysis, including three independent 30 ns simulations of alanine dipeptide and three independent 300 ns simulations of chignolin. For the T4-lysozyme, five independent 800 ns simulations were initially performed. Complete binding of benzene to the target ligand-binding site was observed in one of the five simulations. Even when the simulation was extended to 1,800 ns, benzene remained tightly bound in the ligand-binding cavity. The simulation frames were saved every 0.1 ps for analysis. A summary of the simulations is listed in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}.

Simulation Analysis {#sec2.3}
-------------------

Time courses of dihedral angles, RMSD, radius of gyration (*R*~g~), and residue distances in the AMBER simulation trajectories were analyzed using the *cpptraj* tool.^[@ref24]^ Particularly, the backbone dihedral angles Φ and Ψ were calculated for alanine dipeptide ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A). For chignolin, the *R*~g~ and RMSD of simulation frames relative to the PDB native structure ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A) were calculated for the protein C~α~ atoms with the terminal residues Gly1 and Gly10 excluded. For ligand binding to the T4-lysozyme ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}A), the symmetry-corrected RMSD of benzene was obtained by generating six symmetrically imaged reference benzene configurations from the 181L crystal structure, calculating the RMSDs for the diffusing benzene molecules in each frame after aligning the protein C-terminal domain (residues 80--160) and then extracting the minimum value of the calculated RMSDs. Moreover, the number of protein atoms found within 5 Å of benzene (*N*~contact~, only heavy atoms are considered) was calculated using *pbwithin* in VMD that accounts for the periodic boundary conditions.^[@ref25]^

The *PyReweighting* toolkit^[@ref14]^ was used to reweight the GaMD simulations for calculating the PMF profiles and to examine the boost potential distributions. Two-dimensional (2D) PMF profiles were computed for backbone dihedrals (Φ, Ψ) in alanine dipeptide. A bin size of 6° is selected to balance between reducing the anharmonicity and increasing the bin resolution as discussed earlier.^[@ref14]^ Two-dimensional PMF profiles were also constructed using (RMSD, *R*~g~) for chignolin with a bin size of (1.0 Å, 1.0 Å). For benzene binding to the T4-lysozyme, 2D PMF was constructed using (ligand RMSD, *N*~contact~) with a bin size of (1.0 Å, 5). When the number of simulation frames within a bin is lower than a certain limit (i.e., cutoff), the bin is not sufficiently sampled and thus is excluded for reweighting. The cutoff can be determined by iteratively increasing it until the minimum position of the PMF profile does not change.^[@ref14]^ The final cutoff was set as 10, 50, and 1000 for reweighting of GaMD simulations on alanine dipeptide, chignolin, and T4-lysozyme, respectively.

Results {#sec3}
=======

GaMD provides enhanced sampling of conformational transitions in alanine dipeptide, chignolin folding, and ligand binding to the T4-lysozyme. Furthermore, the boost potential applied in the present GaMD simulations follows Gaussian distribution, which allows accurate reweighting using cumulant expansion to the second order and recovery of the original biomolecular free energy landscapes, even for proteins as large as the T4-lysozyme. Notably, hundreds-of-nanoseconds GaMD simulations are able to capture complete folding of chignolin and ligand binding of benzene to the T4-lysozyme that take place on significantly longer time scales.

Alanine Dipeptide {#sec3.1}
-----------------

In order to balance between achieving the highest acceleration (large Δ*V*) and ensuring accurate reweighting (small enough standard deviation, σ~Δ*V*~), short GaMD simulations (2 ns) were tested on alanine dipeptide to search for optimal acceleration parameters. For the total potential boost, when σ~0P~ was adjusted from 1.0 to 2.0, the resulting *k*~0P~ calculated using [eq [9](#eq9){ref-type="disp-formula"}](#eq9){ref-type="disp-formula"} was increased from 0.21 to 1.0, accompanied by increases of the Δ*V*~P~ standard deviation from 1.03 to 1.75 kcal/mol and the Δ*V*~P~ average from 2.36 to 3.85 kcal/mol (see [Supporting Information](#notes-1){ref-type="notes"} Table S1a). After *k*~0P~ reached its maximum 1.0, slight changes were observed when σ~0P~ was further increased from 2.0 to 3.0. For the dihedral potential boost, the calculated *k*~0D~ reached 1.0 when σ~0D~ was increased to 3.0 ([Supporting Information](#notes-1){ref-type="notes"} Table S1b). Therefore, (σ~0P~,σ~0D~) were set to (3.0, 3.0) for the production dual-boost GaMD simulations of alanine dipeptide, which enables the highest acceleration as well as accurate reweighting with both *k*~0P~ and *k*~0D~ equal to 1.0 ([Supporting Information](#notes-1){ref-type="notes"} Table S1c).

As shown in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B, the boost potential Δ*V* applied in GaMD simulation of the alanine dipeptide follows Gaussian distribution. Its distribution anharmonicity is small enough to be 1.69 × 10^--3^. The average and standard deviation of Δ*V* are 10.9 and 2.9 kcal/mol, respectively ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C plots the 2D PMF of backbone dihedrals (Φ, Ψ) that are obtained by reweighting the three 30 ns GaMD simulations combined using cumulant expansion to the second order. The reweighted PMF is able to recover five energy minimum wells that are centered around (−162°, −12°) and (−72°, −12°) for the right-handed α helix (α~R~), (48°, 18°) for the left-handed α helix (α~L~), (−156°, 162°) for the β-sheet, and (−66°, 156°) for the polyproline II (P~II~) conformation. The corresponding minimum free energies are estimated as 0, 1.40, 1.07, 2.94, and 4.27 kcal/mol, respectively. This is in good agreement with the PMF results of an exceptionally long 1000 ns cMD simulation as presented earlier.^[@ref14]^ Additionally, the distribution anharmonicity of Δ*V*of frames clustered in each bin of the 2D PMF exhibits values smaller than 0.10 in the low-energy regions ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}D), which suggests sufficient sampling for reweighting using cumulant expansion to the second order. Greater anharmonicity is found in high-energy regions (especially the energy barriers), for which low boost potential is applied and less sampling is normally achieved. Therefore, the anharmonicity of Δ*V* distribution appears to be a good indicator for sufficiency of the enhanced sampling and accuracy of the reweighted free energy.

![(A) Scheme representation of backbone dihedrals Φ and Ψ in alanine dipeptide. (B) Distribution of the boost potential Δ*V* applied in the GaMD simulation. (C) 2D potential of mean force (PMF) of backbone dihedrals (Φ, Ψ) calculated from three 30 ns GaMD simulations combined using cumulant expansion to the second order. The low-energy wells are labeled corresponding to the right-handed α helix (α~R~), left-handed α helix (α~L~), β-sheet (β), and polyproline II (P~II~) conformations. (D) Distribution anharmonicity of Δ*V* of frames found in each bin of the PMF profile.](ct-2015-00436c_0003){#fig2}

Folding of Chignolin {#sec3.2}
--------------------

For chignolin, short 2 ns testing GaMD simulations showed that *k*~0P~ reached the 1.0 maximum for the highest total potential boost when σ~0P~ was increased to 3.0 ([Supporting Information](#notes-1){ref-type="notes"} Table S2a). For the dihedral potential boost, the simulation crashed when σ~0D~ was increased to 0.9 and stable simulation was achieved only when σ~0D~ was increased to 0.6 ([Supporting Information](#notes-1){ref-type="notes"} Table S2b). Thus, (σ~0P~,σ~0D~) were set to (3.0, 0.6) for the production dual-boost GaMD simulations of chignolin ([Supporting Information](#notes-1){ref-type="notes"} Table S2c). The resulting boost potential follows Gaussian distribution and the calculated γ = 9.22 × 10^--3^ ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B). The average and standard deviation of Δ*V* are 9.8 and 2.4 kcal/mol, respectively ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}).

![Folding of chignolin captured in GaMD simulations: (A) comparison of simulation-folded chignolin (blue) with the PDB (1UAO) native structure (red) that exhibits 0.2 Å RMSD, (B) distribution of the boost potential Δ*V*, (C) 2D (RMSD, *R*~g~) PMF calculated by reweighting the three 300 ns GaMD simulations combined, and (D) the distribution anharmonicity of Δ*V* of frames found in each bin of the PMF profile.](ct-2015-00436c_0004){#fig3}

Started from an extended conformation, GaMD simulations were able to capture complete folding of chignolin into its native structure ([Supporting Information](#notes-1){ref-type="notes"} Movie S1). The RMSD obtained between the simulation-folded chignolin and NMR experimental native structure (PDB, 1UAO) reaches a minimum of 0.2 Å ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A). Using the protein RMSD relative to the PDB native structure and *R*~g~, a 2D PMF profile was calculated by reweighting the three 300 ns GaMD simulations combined ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C). The reweighted PMF allows us to identify three distinct low-energy conformational states: the folded ("F"), unfolded ("U"), and an intermediate ("I"). The folded state corresponds to the global energy minimum at (1.0 Å, 4.0 Å), the unfolded state is 3.68 kcal/mol higher in a local-energy well centered at (6.0 Å, 7.0 Å), and the intermediate in a 3.06 kcal/mol free energy well centered at (4.0 Å, 5.5 Å). The energy barrier for chignolin folding between the unfolded and folded states is ∼4.0 kcal/mol, and ∼3.5 kcal/mol for transitions between the intermediate and folded states ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C). In comparison, when the three 300 ns GaMD simulations were analyzed separately, the reweighted PMF profiles exhibit significant differences ([Supporting Information](#notes-1){ref-type="notes"} Figure S2). Whereas the three folded, intermediate, and unfolded low-energy states were captured in sim2, the unfolded and intermediate states were not sufficiently sampled (no converged low-energy wells) in sim1 and sim3, respectively. Improved sampling was obtained by combining the three independent GaMD simulations. [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}D plots the distribution anharmonicity of Δ*V* for frames found in each bin of the 2D PMF as shown in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C. The anharmonicity exhibits values smaller than 0.05 in the simulation sampled conformational space, suggesting that Δ*V* achieves sufficient sampling for reweighting using cumulant expansion to the second order.

Compared with the native structure, the unfolded chignolin exhibits an extended conformation without proper secondary structure formed in the protein backbone as shown in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}A. The intermediate conformation observed during folding of chignolin is characterized by hydrophobic interactions between the Pro4 and Trp9 residue side chains and a turn at Thr8. Such conformation was also observed in previous microsecond-time-scale cMD simulations.^[@ref26]^ In the simulation-derived folded state, the protein residue side chains exhibit closely similar conformations as in the NMR native structure ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}C). Residues Tyr2 and Pro4 form hydrophobic interactions between their side chains. Hydrophilic residues Asp3, Glu5, Thr6, and Thr8 expose side chains to the solvent.

![Structures of chignolin observed during GaMD simulations corresponding to the (A) unfolded ("U"), (B) intermediate ("I"), and (C) folded ("F") states (blue) aligned to the PDB native structure (red). Residues including Tyr2, Asp3, Pro4, Glu5, Thr6, Thr8, and Trp9 are represented by sticks. Notably, Trp9 and Pro4 form hydrophobic interactions in the intermediate state.](ct-2015-00436c_0005){#fig4}

Finally, a 2D free energy profile of chignolin was calculated using the RMSD of the protein C~α~ atoms relative to the native PDB structure and the backbone dihedral Ψ of residue Gly7 ([Supporting Information](#notes-1){ref-type="notes"} Figure S3). The three independent 300 ns GaMD simulations were combined for the reweighting. This allows for identification of a misfolded ("M") low-energy state, in addition to the F, I, and U states as observed in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C. The M conformation of chignolin shows ∼180° rotation of the C-terminal strand about its long axis relative to the native PDB structure. The free energy of the misfolded chignolin is found to be 1.89 kcal/mol greater than that of the folded state. This is consistent with previous findings that the misfolded chignolin was observed with higher probability in simulations with the AMBER ff99SB force field,^[@ref27]^ which is used in the present study.

Benzene Binding to T4-Lysozyme {#sec3.3}
------------------------------

Short testing GaMD simulations of the T4-lysozyme showed that *k*~0P~ reached the 1.0 maximum for the highest total potential boost when σ~0P~ was increased to 3.0 ([Supporting Information](#notes-1){ref-type="notes"} Table S3a). For the dihedral potential boost, the simulation crashed when σ~0D~ was increased to 5.0 ([Supporting Information](#notes-1){ref-type="notes"} Table S3b). Stable simulation was achieved when σ~0D~ was increased to 4.0 and the calculated *k*~0D~ was 0.35. With further testing for stable dual-boost GaMD simulation, (σ~0P~,σ~0D~) were set to (3.0, 4.0) for the final production simulations of the T4-lysozyme ([Supporting Information](#notes-1){ref-type="notes"} Table S3c).

GaMD captured complete binding of benzene to the deeply buried ligand-binding cavity in the Leu99Ala T4-lysozyme within ∼100 ns in one of the five independent 800 ns simulations ([Supporting Information](#notes-1){ref-type="notes"} Movie S2). Benzene remained bound in the ligand-binding site even when the simulation was extended to 1,800 ns. By aligning the C-terminal domain (residues 80--160) of the T4-lysozyme, the RMSD of the diffusing benzene molecules relative to the bound pose in the 181L X-ray crystal structure reaches a minimum of 0.1 Å ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}A). The boost potential applied during the 1,800 ns GaMD simulation follows Gaussian distribution, and its γ = 1.39 × 10^--3^ ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}B). The average and standard deviation of Δ*V* are 36.5 and 4.7 kcal/mol, respectively ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Although the Δ*V* average values exhibit variations between five independent simulations, the Δ*V* standard deviations are closely similar to each other provided that (σ~0P~,σ~0D~) were set to (3.0, 4.0) ([Supporting Information](#notes-1){ref-type="notes"} Table S3c). Using the RMSD of benzene relative to the bound pose and the number of protein heavy atoms that are within 5 Å of benzene (*N*~contact~), a 2D PMF profile was calculated by reweighting the 1,800 ns GaMD simulation ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}C). The reweighted PMF allows us to identify three distinct low-energy states: the unbound ("U"), intermediate ("I"), and bound ("B") states. The bound state corresponds to the global energy minimum located at ∼(0 Å, 30), the unbound state in a local-energy well centered at ∼(33 Å, 0), and the intermediate centered at ∼(11 Å, 20). It is important to note that since the complete binding of benzene to the target ligand-binding site was observed only once, the calculated binding free energy between the bound and unbound states is subject to the error of limited sampling. Nevertheless, benzene visits the intermediate site many times during the 1800 ns GaMD simulation with the ligand RMSD decreased to ∼11 Å ([Supporting Information](#notes-1){ref-type="notes"} Figure S2A). Repeated sampling of the intermediate state was observed in the other four 800 ns GaMD simulations as well ([Supporting Information](#notes-1){ref-type="notes"} Figure S2), for which a local-energy well appears around (11.0 Å, 20) in the 2D PMF profiles ([Supporting Information](#notes-1){ref-type="notes"} Figure S3). The relative free energy between the intermediate and unbound states is estimated to be 0.53 ± 0.46 kcal/mol from PMF profiles of the five GaMD simulations. Furthermore, benzene was observed to bind another intermediate 2 ("I2") site that is located in the pocket formed by the hinge α~C~ helix and the α~B~ helix from the N-terminal domain ([Supporting Information](#notes-1){ref-type="notes"} Figure S2). A corresponding local energy well of the I2 state appears in the calculated 2D PMF profiles. [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}D plots the Δ*V* distribution anharmonicity, γ, for frames found in each bin of the 2D PMF. It exhibits relatively large values in the high-energy regions (less sampling), notably the energy barrier between the intermediate and bound states. The ligand entry from the intermediate to the bound state is thus suggested to be the rate-limiting step for benzene binding. In comparison, γ exhibits values smaller than 0.01 in the energy well regions, suggesting that Δ*V* achieves sufficient sampling for reweighting using cumulant expansion to the second order.

![Binding of benzene to the Leu99Ala T4-lysozyme simulated via GaMD: (A) comparison of simulation-derived complex structure that captures benzene binding (blue) with 0.1 Å ligand RMSD relative to the 181L PDB structure (red), (B) distribution of the boost potential Δ*V*, (C) 2D (ligand RMSD, *N*~contact~) PMF calculated by reweighting the 1,800 ns GaMD simulation, and (D) distribution anharmonicity of Δ*V* of frames found in each bin of the free energy profile.](ct-2015-00436c_0006){#fig5}

A complete binding pathway of benzene that was observed in the GaMD simulation is shown in [Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}A. Benzene diffuses from the bulk solvent to the protein surface formed by the α~D~ and α~G~ helices and then to the target ligand-binding site in the protein C-terminal domain. [Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}B depicts the unbound pose of a benzene molecule that is located far away from the ligand-binding site in the 181L X-ray crystal structure. In the intermediate state, benzene interacts with residues Lys83, Pro86, and Val87 from the α~D~ helix and the Thr115, Thr119, and Gln122 residues from the α~G~ helix ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}C). In the bound pose, benzene is superimposable with the ligand cocrystallized in the 181L crystal structure. It forms hydrophobic interactions with residues Ile78, Leu84, Tyr88, Val87, Leu91, Val111, Leu118, and Leu121 in the deeply buried protein cavity ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}D). [Supporting Information](#notes-1){ref-type="notes"} Figure S5 shows a transient snapshot observed during benzene binding between the intermediate and bound poses. Benzene appears to slide into the ligand-binding cavity, interacting with residues Gln81, Lys83, Leu84, Val111, Phe114, Thr115, and Leu118 from the α~D~, α~F~, and α~G~ helices.

![(A) Pathway of benzene binding to the T4-lysozyme observed during the GaMD simulation. (B--D) The (B) unbound ("U"), (C) intermediate ("I"), and (D) bound ("B") poses of the protein--ligand complex (blue) with the protein C-terminal domain (residues 80--160) aligned to the PDB native structure (red). The protein and benzene are represented by ribbons and spheres, respectively, and they are colored by blue for the simulation structure while red for the PDB native structure, except that in A the simulated benzene is represented by lines and colored by simulation time in a BWR color scale. Residues with heavy atoms found within 3 Å of benzene are represented by sticks.](ct-2015-00436c_0007){#fig6}

Discussion {#sec4}
==========

By adaptively adding a harmonic boost potential to smoothen the system energy surface, GaMD provides both unconstrained enhanced sampling and free energy calculation of biomolecules. Important statistical properties of the system potential, such as the average, maximum, minimum, and standard deviation values, are used to calculate the simulation acceleration parameters, particularly the threshold energy, *E*, and force constant, *k*~0~.

For alanine dipeptide, both *k*~0P~ and *k*~0D~ can be increased to the 1.0 maximum for the greatest possible boost of the total and dihedral potential energies. The resulting standard deviation of Δ*V* that follows Gaussian distribution is 2.9 kcal/mol, which allows for accurate reweighting using cumulant expansion to the second order. Notably, high-energy regions of the GaMD sampled free energy surface (especially the energy barriers) exhibit increased anharmonicity compared with the low-energy wells ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}D). Thus, the free energy barriers appear unconverged and still suffer from insufficient sampling during the three short 30 ns GaMD simulations. Nevertheless, the GaMD reweighted PMF profile is able to recover low-energy states of the system that are in good agreement with those observed in a 1000 ns cMD simulation.^[@ref14]^

Furthermore, GaMD is able to fold chignolin from an extended conformation to the NMR native structure in three independent 300 ns simulations. While *k*~0P~ can be increased to 1.0 for the greatest total potential boost, *k*~0D~ can reach only 0.15--0.17 for stable simulation. Nevertheless, this seems to provide sufficient sampling of the chignolin-folding process. Among the three independent simulations, although the folded, intermediate, and unfolded low-energy states are captured in sim2, the unfolded and intermediate states are not sufficiently sampled in sim1 and sim3, respectively ([Supporting Information](#notes-1){ref-type="notes"} Figure S2). More sufficient sampling is obtained by combining the three GaMD simulations. All three folded, intermediate, and unfolded states are identified from the resulting reweighted free energy profiles. Particularly, the intermediate conformation was also observed in earlier microsecond-time-scale cMD simulations.^[@ref26]^ GaMD appears to achieve better convergence than the previous aMD simulations that were not able to distinguish between the intermediate and unfolded states within the same simulation time.^[@ref28]^

Finally, GaMD captured complete binding of benzene to the ligand-binding site of the T4-lysozyme. In one of the five independent simulations, benzene diffused into the deeply buried ligand-binding cavity within ∼100 ns and remained bound even when the simulation was extended to 1800 ns. Similar to chignolin, while *k*~0P~ can be increased to the 1.0 maximum for the greatest total potential boost in the T4-lysozyme simulations, *k*~0D~ can reach only 0.33--0.35 for the greatest dihedral boost. The resulting Δ*V* standard deviation is ∼4.7 kcal/mol in the final dual-boost GaMD simulations. Such narrow distribution of Δ*V* ensures accurate reweighting using cumulant expansion to the second order. Distinct low-energy unbound, intermediate, and bound states were identified from the reweighted PMF profiles. The atomistic GaMD simulation also elucidates a highly detailed binding pathway of benzene that diffuses from the bulk solvent to an intermediate site located on the protein surface formed by the α~D~ and α~G~ helices and then slides into the target ligand-binding cavity through a channel formed by the α~D~, α~F~, and α~G~ helices. The free energy difference between the intermediate and unbound states was found to be small at 0.53 ± 0.46 kcal/mol as estimated from the five independent GaMD simulations. Benzene repeatedly visits the intermediate site on the protein surface. In comparison, the ligand entry from protein surface to the deeply buried protein cavity appears to be the rate-limiting step for complete benzene binding. It is important to note that the complete ligand binding was not observed in the four 800 ns GaMD simulations, suggesting that the present GaMD simulations still suffer from insufficient sampling of the ligand entry process and the reweighted free energy profiles remain unconverged ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}C and [Supporting Information](#notes-1){ref-type="notes"} Figure S5). This is also indicated by the increased anharmonicity corresponding to the free energy barrier between the intermediate and bound states as shown in [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}D. Nevertheless, our GaMD simulation captured a binding pathway of benzene to the T4-lysozyme. The ligand entry site is indeed adjacent to the mobile α~F~ helix (residues 108--113), which has been suggested earlier^[@ref29]^ based on the finding that the α~F~ helix exhibits increased B-factors in the Leu99Ala complex structures compared to the apo structures.^[@ref30]^

Here, GaMD is compared with the original aMD, particularly on the performance of smoothening the potential energy surface and energetic reweighting. [Supporting Information](#notes-1){ref-type="notes"} Table S4 summarizes the statistical properties of the boost potential and the original and modified potential energies as obtained from aMD and GaMD simulations of the alanine dipeptide, chignolin, and T4-lysozyme, with reference to the cMD simulations. Specifically, dual-boost aMD simulations of the alanine dipeptide and chignolin obtained from our previous study^[@ref14]^ were used for comparison. For the T4-lysozyme, restarting from the initial configuration of GaMD simulations, a 200 ns dual-boost aMD simulation was performed using the following acceleration parameters: *E*~dihed~ = *V*~dihed_av~ + 4*N*~res~, α~dihed~ = 4*N*~res~/5, *E*~total~ = *V*~total_av~ + 0.2*N*~atoms~, and α~total~ = 0.2*N*~atoms~, where *V*~dihed_av~ and *V*~total_av~ are the average dihedral and total potential energies calculated from a short 10 ns cMD simulation. As shown in [Supporting Information](#notes-1){ref-type="notes"} Table S4, although higher average boost potentials are applied in GaMD simulations of the three systems than in the aMD simulations, the boost potentials exhibit smaller standard deviations (i.e., narrower distribution) in the GaMD simulations, except for the alanine dipeptide. Furthermore, anharmonicity of the boost potential distribution is significantly reduced in the GaMD simulations. Relative to cMD, both aMD and GaMD simulations mostly exhibit smaller standard deviations in the modified dihedral and total potential energies. Notably for the T4-lysozyme, standard deviations of the modified potential energies are significantly smaller in the GaMD simulations than in aMD. Thus, the potential energy surfaces appear more smoothened in GaMD enhanced sampling of the T4-lysozyme. Provided the narrower distribution and lower anharmonicity of the boost potential ([Supporting Information](#notes-1){ref-type="notes"} Table S4), GaMD allows for more accurate approximation of exponential average reweighting factor using cumulant expansion to the second order and thus improved free energy calculation, especially for the T4-lysozyme.

In the present simulations of ligand binding to the T4-lysozyme, complete binding of benzene was observed only once, largely because the target ligand-binding site is deeply buried in the protein. However, benzene binding to the intermediate site on the protein surface formed by the α~D~ and α~G~ helices was captured many times, which provides better statistics for free energy calculation. It has been suggested that a PMF-based approach is appropriate to calculate binding free energy for ligands (especially the charged) that bind to the protein surface.^[@ref31]^ Systems of this type for future applications of GaMD might include binding of benzamidine to trypsin^[@ref32]^ and allosteric modulators to the protein surface of the G-protein coupled receptors.^[@ref33]^

In comparison with many enhanced sampling methods such as umbrella sampling,^[@ref4]^ conformational flooding,^[@ref5]^ metadynamics,^[@ref6]^ ABF calculations,^[@ref7]^ and orthogonal space sampling,^[@ref8]^ GaMD has the advantage of no need to set predefined reaction coordinates. Metadynamics, in particular, is another potential biasing technique that has been widely used to map the free energy landscapes of biomolecules such as protein conformational changes^[@ref34]^ and protein--ligand binding.^[@cit6b],[@ref35]^ By monitoring the energy surface of biomolecules during the simulation, metadynamics keeps adding small Gaussians of potential energies to the low-energy regions. This will eventually fill the low-energy wells and achieve uniform sampling of the free energy surface along selected reaction coordinates. The usage of predefined coordinates greatly reduces the complexity of biomolecular simulation problems and facilitates the free energy calculations (e.g., significantly lower energetic noise compared with aMD simulations). However, it is key to select proper reaction coordinates, which often requires expert knowledge of the studied systems. Construction of biomolecular reaction coordinates or collective variables has thus been one of the main objectives in metadynamics studies.^[@cit6a]^ When important reaction coordinates are missed during the simulation setup, metadynamics simulations may suffer from slow convergence problems as discussed earlier. Furthermore, the predefined reaction coordinates tend to place constraints on the sampled space and pathways. It seems difficult to identify certain intermediate states during the protein-folding and ligand-binding pathways, e.g., intermediate 2 as observed during the binding of benzene to the T4-lysozyme. In comparison, aMD simulations are not constrained by reaction coordinates, but this also leads to much higher energetic noise and presents grand challenge for accurate reweighting to recover the original free energy landscapes of biomolecules.^[@ref12]^ Although cumulant expansion to the second order was shown to improve aMD reweighting when the boost potential follows near Gaussian distribution,^[@ref14]^ such improved reweighting is still limited to small systems such as protein with ≤35 residues.^[@ref15]^ Here, by constructing boost potential using a harmonic function that follows Gaussian distribution, GaMD enables rigorous energetic reweighting through cumulant expansion to the second order, even for simulations of larger proteins (e.g., T4-lysozyme). With this, GaMD achieves simultaneous unconstrained enhanced sampling and free energy calculations.

However, several cautions also result from this study. First, while the present GaMD simulations seem to provide sufficient sampling of the low-energy regions, they appear to remain unconverged in sampling of the high-energy barriers. This is particularly true for the ligand entry step in the GaMD simulation of benzene binding to the T4-lysozyme. It is worth recalling that the threshold energy for adding the boost potential is set to its lower bound in the present GaMD simulations. It is subject to future investigation into whether using the upper bound of the threshold energy will facilitate sampling of the high-energy barriers in GaMD simulations. Second, based on a potential biasing approach, GaMD mainly accelerates transitions across enthalpic energy barriers. Improvement for its application to systems with high entropic barriers is still in need. On this regard, GaMD can be potentially combined with the parallel tempering^[@ref36]^ and replica exchange^[@ref37]^ algorithms for further enhanced sampling. Particularly, the combination of parallel tempering and metadynamics (PT-MetaD)^[@cit34a]^ has been shown to facilitate enhanced sampling of biomolecules over entropic barriers.

In summary, without the need to set predefined reaction coordinates, GaMD is generally applicable to a wide range of biomolecular systems as demonstrated on protein folding and ligand binding in this study. For systems of increasing size, the upper limit of the Δ*V* standard deviation, σ~0~ can be adjusted dynamically to ensure that the distribution width of the applied boost potential is narrow enough for accurate energetic reweighting using cumulant expansion to the second order. Therefore, GaMD provides both unconstrained enhanced sampling and free energy calculation for biomolecular simulations.

Gaussian accelerated molecular dynamics (GaMD) is currently implemented in the GPU version of AMBER 12,^[@ref17]^ but should be transferable to AMBER 14 and other molecular dynamics programs as well. GaMD provides enhanced sampling of biomolecules by adding a harmonic boost potential to smoothen the system potential energy surface. Following is a list of the input parameters for a GaMD simulation:The GaMD algorithm is summarized as the following:

For simulations of a biomolecular system, the probability distribution along a selected reaction coordinate *A*(***r***) is written as *p*\*(*A*), where ***r*** denotes the atomic positions {***r***~1~,\...,***r***~*N*~}. Given the boost potential Δ*V*(***r***) of each frame, *p*\*(*A*) can be reweighted to recover the canonical ensemble distribution, *p*(*A*), aswhere *M* is the number of bins, β = *k*~B~*T* and ⟨*e*^βΔ*V*(***r***)^⟩~*j*~ is the ensemble-averaged Boltzmann factor of Δ*V*(***r***) for simulation frames found in the *j*th bin. In order to reduce the energetic noise, the ensemble-averaged reweighting factor can be approximated using cumulant expansion:^[@ref38]^where the first three cumulants are given byAs shown earlier, when the boost potential follows near-Gaussian distribution, cumulant expansion to the second order provides the more accurate reweighting compared with the exponential average and Maclaurin series expansion methods.^[@ref14]^ Finally, the reweighted free energy is calculated as *F*(*A*~*j*~) = −(1/β) ln *p*(*A*~*j*~).

Test GaMD simulations and comparison of GaMD and aMD (Tables S1--S4), RMSD and *R*~g~ plots, free energy profiles and misfolded conformation of chignolin, GaMD simulations of ligand binding to T4-lysozyme, PMF profiles, intermediate 2 state of ligand binding to T4-lysozyme, and transition snapshot of benzene binding to T4-lysozyme (Figures S1--S7), and protein folding and protein--ligand binding (Movies S1--S2). The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acs.jctc.5b00436](http://pubs.acs.org/doi/abs/10.1021/acs.jctc.5b00436).
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